2024-11-01 I-Mab Biopharma HaiPress
ROCKVILLE,Md.,Oct. 31,2024 -- I-Mab (NASDAQ: IMAB) (the "Company"),a US-based,global biotech company,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer,today announced that it plans to release financial results for the third quarter ended September 30,2024,on Thursday,November 14,pre-market Eastern Time.
The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline,corporate strategy,and objectives. Information about financial results,conference calls,webcasts,and other information is posted on the Company's website.
AboutI-Mab
I-Mab (NASDAQ: IMAB) is a US-based,exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in Rockville,Maryland,and Short Hills,New Jersey.For more information,please visithttps://www.i-mabbiopharma.comand followus onLinkedInandX.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director,Investor Relations
IR@imabbio.com
Federal Reserve Data Released: Industrial Output Continues to Decline
State Grid Bortala Power Supply Company: Achieving the Application of Feeder Automation
China Matters' Feature: Beidahuang: Green Development on Black Soil
Hong Kong Screen Legend Chow Yun Fat Hosts Charity Photography Exhibition "Hong Kong‧Morning" at Harbour City, Showcasing 30 Stunning City Photographs
GEEKOM's high-performance mini PCs will shine at CES2025
Potech Group Expands Global Presence with New Entity Launch in Australia
©copyright 2009-2020 Singapore Info Map